Summary
In a double-blind, placebo cross-over study in 14 patients with Raynaud's disease, oral ketanserin 40 mg b.d. for two months reduced the number of digital ischaemic attacks in 36% of the patients, with no difference between primary or secondary cases. Intraplatelet and circulating serotonin concentrations were significantly higher in patients than in controls. During treatment there was a significant decrease in intraplatelet serotonin, but no change in circulating serotonin or in the amount of serotonin released by platelets in vitro. The results suggest that oral ketanserin is of minor help in Raynaud's phenomenon and they support a role for serotonin in the disorder.
This is a preview of subscription content, log in via an institution to check access.
References
Halpern A, Kuhn PH, Shaftel HE, Samuels SS, Shaftel N, Selman D, Birch HG (1960) Raynaud's disease, Raynaud's phenomenon and serotonin. Angiology 11: 151–167
Seibold JR (1985) Serotonin and Raynaud's phenomenon. In: Vanhoutte PM (ed) Serotonin and the cardiovascular system. Raven Press, New York
Allen EV, Brown GE (1932) Raynaud's disease: A critical review of minor requisites for diagnosis. Am J Med Sci 183: 187–200
Marasini B, Biondi ML, Barbesti S, Zatta G, Agostoni A (1986) Cigarette smoking and platelet function. Thromb Res 44: 85–94
Born GVR (1966) Aggregation of blood platelets by adenosine-diphosphate and its reversal. Nature 194: 927–929
Biondi ML, Marasini B, Bianchi E, Agostoni A (1988) Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon. Internat J Cardiol 19: 335–339
Baart de la Faille H, Van Weelden H, Banga SD, Van Kesteren RG (1986) Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: A double-blind cross-over study. Arch Dermatol Res 279: 3–7
Seibold JR, Terregino CA (1986) Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold-induced vasoconstriction in primary Raynaud's phenomenon. J Rheumatol 13: 337–340
Tomlison IW (1985) Monitoring cutaneous circulation. In: Davis E (ed) Raynaud's phenomenon with observations on ketanserin, Raynaud update: Pathophysiology and treatment. Advances in Microcirculation vol 12. Karger, Basel
Lukàc J, Rovensky J, Tauchmannovà H, Zitnan D (1985) Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: A double-blind trial. Drugs Exp Clin Res XI: 659–663
Roald OK, Seem E (1984) Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders. Br Med J 289: 577–579
Van de Wal HJCM, Wijn PFF, Van Lier HJJ, Skotnicki SH (1985) Quantitative study of the effects of ketanserin in patients with primary Raynaud's phenomenon. Microcirc Endothelium Lymphatics 2: 657–685
Bounameaux HH, Hellemans H, Verhaeghe R, Dequeker J (1984) Ketanserin (5-HT-antagonist) in secondary Raynaud's phenomenon (letter). J Cardiovasc Pharmacol 6: 975–976
Seibold JR, Jageneau AHH (1984) Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin (5-HT) receptor. Arthritis Rheum 27: 139–146
De Clerck F, David JL, Janssen PAJ (1982) Serotonergic amplification mechanisms in blood platelets. In: De Clerck F, Vanhoutte PM (eds) 5-Hydroxytryptamine in peripheral reactions. Raven Press, New York
Bevan J, Heptinstall S (1983) Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets. Thromb Res 30: 415–423
Amery A, Fagard R, Fiocchi R, Lijnen P, Staessen J, Vermylen J (1984) Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients. J Cardiovasc Pharmacol 6: 182–185
Baumgartner HR, Born GVR (1968) Effects of 5-hydroxytryptamine on platelet aggregation. Nature 218: 137–141
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marasini, B., Biondi, M.L., Bianchi, E. et al. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon. Eur J Clin Pharmacol 35, 419–421 (1988). https://doi.org/10.1007/BF00561375
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561375